Showing 4541-4550 of 9153 results for "".
- Wound Repair Breakthrough: Protein Coacervates Engineered Into Adhesive for “Unprecedented” Skin Repair Speedhttps://practicaldermatology.com/news/wound-repair-breakthrough-protein-coacervates-engineered-into-adhesive-for-unprecedented-skin-repair-speed/2462032/A team of researchers from China is developing a novel biocomposite adhesive that may revolutionize wound management and tissue repair, according to a study in Engineering.
- DEF, SDPA Call Attention to Heart Health for World Heart Dayhttps://practicaldermatology.com/news/def-sdpa-call-attention-to-heart-health-for-world-heart-day/2462027/The Dermatology Education Foundation (DEF) and the Society of Dermatology Physician Assistants (SDPA) are calling on NPs and PAs in dermatology to take charge of their own health and support peers in recognition of World Heart Day on September 29, 2023. “As nurse practitioner
- Study: Test Kids With AD for Allergic Contact Dermatitishttps://practicaldermatology.com/news/study-test-kids-with-ad-for-allergic-contact-dermatitis/2462025/Children with atopic dermatitis may also need to be tested for allergic contact dermatitis, according to a new study in the
- Cosmo, Glenmark Sign Distribution and License Agreements for Winlevi in Europe and South Africahttps://practicaldermatology.com/news/cosmo-glenmark-sign-distribution-and-license-agreements-for-winlevi-in-europe-and-south-africa/2462024/Glenmark Pharmaceuticals Ltd., now has exclusive rights to commercialize Winlevi (clascoterone cream 1%) in 15 EU countries (Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal,
- Revealed: Why Skin Feels “Tight” After Using a Facial Cleanserhttps://practicaldermatology.com/news/revealed-why-skin-feels-tight-after-using-a-facial-cleanser/2462023/Some cleansers make the skin feel “tight” and some moisturizers make the skin feel “soft,” but exactly why this occurs hasn't been fully understood. To find out, Reinhold H. Dauskardt, the Ruth G. and William K. Bowes Professor in Stanford’s
- ASDS: Dermatologists Remain the Primary Influencer for Patients’ Cosmetic Procedures, Skin Care Decisionshttps://practicaldermatology.com/news/asds-dermatologists-remain-the-primary-influencer-for-patients-cosmetic-procedures-skin-care-decisions/2462022/Board certified dermatologists hold the most sway when it comes to choosing a provider, cosmetic procedure, or skin care product, according to the
- Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-initiates-clinical-proof-of-concept-study-of-ep262/2462020/The first patient has been dosed in Escient Pharmaceuticals CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262, a first-in-class oral MRGPRX2 antagonist for chronic inducible urticaria. By blocking activation of MRGPRX2 and degranulation of mast cells,
- Colloidal Oatmeal Cream Soothes AD in Black Childrenhttps://practicaldermatology.com/news/colloidal-oatmeal-cream-soothes-ad-in-black-children/2462018/Oatmeal cream may help ease atopic dermatitis in Black children, according to research presented at the Science of Skincare Summit in Austin, Texas. Black children are 1.7 times more likely to dev
- CeraVe Funds New Derm Residency Position at George Washington Universityhttps://practicaldermatology.com/news/cerave-funds-new-derm-residency-position-at-george-washington-university/2462012/CeraVe is partnering with George Washington University to support a newly approved Accreditation Council for Graduate Medical Education (ACGME) residency spot in the school's Department of Dermatology Resident Program, slated to begin on July 1, 2024. "
- Positive Topline Results Seen for Roflumilast Cream 0.05% in Young Kidshttps://practicaldermatology.com/news/positive-topline-results-seen-for-roflumilast-cream-005-in-young-kids/2462010/Arcutis Biotherapeutics, Inc.’s roflumilast cream 0.05% met all primary endpoint and all secondary endpoints in children aged 2 to 5 years with mild to moderate atopic dermatitis (AD), according to results from the INTEGUMENT-PED pivotal Phase 3 trial. In